載入...
Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers
BACKGROUND: Treatment with apremilast has recently demonstrated clinically meaningful improvement in moderate hidradenitis suppurativa (HS). OBJECTIVE: To evaluate the change in expression of inflammatory markers in lesional skin of HS patients receiving apremilast 30 mg twice daily (n = 15) for 16 ...
Na minha lista:
| 發表在: | J Eur Acad Dermatol Venereol |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6590194/ https://ncbi.nlm.nih.gov/pubmed/30451329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.15354 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|